Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
3.860
-0.020 (-0.52%)
At close: Sep 16, 2026, 4:00 PM EDT
3.729
-0.131 (-3.39%)
After-hours: Sep 16, 2026, 4:09 PM EDT
Myriad Genetics Employees
Myriad Genetics had 2,700 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
2,700
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$298,741
Profits / Employee
-$41,704
Market Cap
367.77M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,700 | 0 | - |
| Dec 31, 2024 | 2,700 | 0 | - |
| Dec 31, 2023 | 2,700 | 100 | 3.85% |
| Dec 31, 2022 | 2,600 | 200 | 8.33% |
| Dec 31, 2021 | 2,400 | -300 | -11.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| OPKO Health | 2,275 |
| Fulgent Genetics | 1,315 |
| Castle Biosciences | 1,002 |
| Burning Rock Biotech | 667 |
| Freenome | 381 |
| MDxHealth | 364 |
| Biodesix | 334 |
| Personalis | 260 |
MYGN News
- 8 hours ago - Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial - GlobeNewsWire
- 6 days ago - Myriad Genetics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 7 days ago - Myriad Genetics assumed with a Neutral at UBS - TheFly
- 15 days ago - This Biotech Stock Got a Rare Double-Downgrade. Its Profitability Problem Just Got Worse. - Barrons
- 15 days ago - Myriad Genetics downgraded to Underweight from Overweight at Piper Sandler - TheFly
- 20 days ago - Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Myriad Genetics price target lowered to $3 from $5 at Stephens - TheFly
- 5 weeks ago - MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law - Business Wire